Wegovy Pill vs Wegovy Injection: Same Drug, Different Form
Same molecule, same company, radically different experience. Since December 2025, Wegovy is available as both a daily pill and a weekly injection. The pill eliminates needles and costs a fraction of the price — but it comes with a strict fasting requirement and uses a 50mg dose to compensate for ~1% oral bioavailability. Here's what you need to know to choose between them.
Efficacy: Remarkably Similar Results
The big surprise: the pill matches the injection.
Despite oral semaglutide having only ~1% bioavailability (compared to nearly 100% for the injection), Novo Nordisk compensated by using a much larger dose — 50mg daily for the pill vs 2.4mg weekly for the injection.
Head-to-head results:
- Wegovy Pill (OASIS-1, 50mg): 15.1% weight loss (ITT) / 16.6% (completers) over 68 weeks
- Wegovy Injection (STEP-1, 2.4mg): 14.9% weight loss (ITT) / ~17% (completers) over 68 weeks
These results are statistically comparable. The pill achieves essentially the same weight loss as the injection. This is a landmark achievement in drug delivery — getting a peptide to work orally at the same efficacy as an injection.
Important caveat: These are cross-trial comparisons (OASIS-1 vs STEP-1), not a direct head-to-head study. Patient populations differed slightly. However, the results are close enough that most experts consider them equivalent.
Convenience: Different Trade-offs
Neither form is universally more convenient — it depends on your lifestyle:
Wegovy Pill pros:
- No needles — no injection anxiety, no sharps disposal
- No cold storage — easier to travel with
- No visible injection device
Wegovy Pill cons:
- Must be taken on an empty stomach every morning
- Only ≤4 oz of plain water to swallow
- 30-minute wait before eating, drinking, or other medications
- Daily commitment vs weekly injection
Wegovy Injection pros:
- Once weekly — only 52 doses per year vs 365
- No food restrictions at all
- Can inject any time of day
- Less daily mental load
Wegovy Injection cons:
- Requires injection (needle, albeit a small auto-injector)
- Needs refrigeration before first use
- Sharps disposal required
- Injection site reactions (~6% in STEP trials)
Bottom line: If you dislike needles and don't mind the fasting routine, choose the pill. If you'd rather deal with one weekly injection than a daily fasting requirement, choose the injection. Both have valid trade-offs.
Cost: The Pill Is a Game-Changer
This is the pill's biggest advantage:
- Wegovy Pill: $149/mo (1.5mg, 4mg doses) to $299/mo (higher doses) self-pay
- Wegovy Injection: ~$1,349/mo list price
That's a 77–89% cost reduction for the pill compared to the injection. For the ~16 million Americans without GLP-1 insurance coverage, this price difference is the deciding factor.
Why is the pill so much cheaper?
- Pills are dramatically cheaper to manufacture than prefilled injection pens
- No cold chain logistics required
- Novo Nordisk priced it aggressively to compete with Foundayo ($149–349/mo)
- Broader accessibility was a stated company goal
With savings cards: Both drop to ~$25/mo for eligible commercially insured patients, making the cost difference irrelevant for many insured patients.
The strategic implication: The pill's pricing effectively makes the injection's list price unsustainable for self-pay patients. Expect the injection to remain primarily an insurance-covered product.
Side Effects: Similar but Not Identical
Since both deliver the same molecule (semaglutide), the GI side effect profile is broadly similar:
Wegovy Pill (OASIS-1, 50mg):
- Nausea: ~31%
- Diarrhea: ~18%
- Vomiting: ~21%
- Constipation: ~14%
Wegovy Injection (STEP-1, 2.4mg):
- Nausea: ~44%
- Diarrhea: ~30%
- Vomiting: ~24%
- Constipation: ~24%
- Injection site reactions: ~6%
Surprisingly, the pill appears to have lower GI side effect rates. This may be because oral semaglutide reaches target tissues through the portal circulation (via the gut), producing a different pharmacokinetic profile than subcutaneous injection. The pill also eliminates injection site reactions entirely.
Note: Cross-trial comparison limitations apply. These were different trials with different patient populations and different reporting standards.
Switching Between Pill and Injection
Many patients will consider switching forms — especially from injection to pill to save money.
Injection → Pill:
- Start the pill the day after your last injection
- Begin at the lowest pill dose and titrate up per your doctor's guidance
- Expect similar efficacy once you reach the maintenance pill dose
- There may be a brief period of reduced drug effect during the transition as the injection clears and the pill dose ramps up
Pill → Injection:
- Less common but may be relevant if you can't maintain the fasting routine
- Start the injection the day after your last pill
- Your doctor may start at a lower injection dose to manage the switch
Key consideration: If you're on the injection and it's working well, the main reason to switch is cost. If your insurance covers the injection at $25/mo, there's no financial incentive to switch. If you're paying $1,349/mo out-of-pocket, the pill at $149–299/mo is a no-brainer.
Compare Your Personalized Switch Plan
Frequently Asked Questions
Sources
- OASIS-1 Phase 3 Trial — oral semaglutide 50mg weight loss data
- STEP-1 Phase 3 Trial — semaglutide 2.4mg injection weight loss data
- SELECT Cardiovascular Outcomes Trial — semaglutide injection (NEJM, 2023)
- Novo Nordisk pricing announcements and Wegovy pill prescribing information, 2025–2026
Don't miss price changes
GLP-1 prices are changing — stay ahead
Foundayo prices may increase — get alerts before they do. Track price drops, shortages, and new switching guidance without checking back manually.
- Price increase warnings before they hit
- Savings card and coupon alerts
- New switching guidance and availability updates
No spam. Unsubscribe anytime. We never share your email.
Ready to Start? Talk to a Doctor Today
Get a prescription in as little as 24 hours — no in-person visit required.
These vetted telehealth providers specialize in GLP-1 prescriptions.
MedSwitcher may earn a commission from some providers. This does not affect our recommendations. Our switch plans are based on clinical data, not partnerships.
Recommended Products
Supplies and tools commonly used by GLP-1 patients during their treatment journey.
As an Amazon Associate, MedSwitcher earns from qualifying purchases. Product links do not affect our clinical recommendations.